Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab versus conventional drugs in axial spondyloarthritis
ChiCTR2100053455Phase 4Recruiting
- Sponsor
- Guangxi Medical University Second Affiliated Hospital
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adalimumab in axial spondyloarthritis (axSpA) (3 arms), sponsored by Guangxi Medical University Second Affiliated Hospital. Primary endpoints: Blood routine examination, Urine routine examination and 4 more. Started Jan 2022; status: recruiting.
02
Drugs
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on ChiCTR2100053455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053455.